Related Experiment Video

Updated: Feb 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.5K

Role of crizotinib in c-mesenchymal-epidermal transition-positive nonsmall cell lung cancer patients

U Batra1, A Jain1, M Sharma1

  • 1Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.

Indian Journal of Cancer
|December 5, 2017
PubMed

Insights

Crizotinib effectively treats non-small cell lung cancer (NSCLC) with cMET amplification, a resistance mechanism to EGFR TKIs. This case series shows partial response in three NSCLC patients with cMET amplification treated with Crizotinib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) incidence is rising, with growing insights into its molecular drivers.
  • cMET amplification is a key mechanism of resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs).

Observation:

  • This case series focuses on three patients diagnosed with NSCLC.
  • All three patients presented with cMET amplification.
  • These patients had previously developed resistance to EGFR TKIs.

Findings:

  • Crizotinib demonstrated anti-tumoral activity in all three cMET-amplified NSCLC patients.
  • All patients achieved a partial response following Crizotinib treatment.
  • This highlights Crizotinib's efficacy in a specific NSCLC subset.

Implications:

  • Crizotinib can be a viable therapeutic option for NSCLC patients with cMET amplification.
  • Targeting cMET amplification may overcome resistance to other therapies.
  • Further research into cMET-driven NSCLC is warranted.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K